|本期目录/Table of Contents|

[1]徐 辉综述,阎 昭审校.苯达莫司汀代谢相关基因的单核酸多态性研究进展[J].天津医科大学学报,2016,22(02):178-181.
点击复制

苯达莫司汀代谢相关基因的单核酸多态性研究进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
22卷
期数:
2016年02期
页码:
178-181
栏目:
综述
出版日期:
2016-03-20

文章信息/Info

Title:
-
文章编号:
1006-8147（2016）02-0178-04
作者:
徐 辉综述; 阎 昭审校
（天津医科大学肿瘤医院国家临床药物试验机构，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津 300060）
Author(s):
-
关键词:
苯达莫司汀; 代谢; SNP; hOCT1; CYP1A2; GST
Keywords:
-
分类号:
R968
DOI:
-
文献标志码:
A
摘要:
-
Abstract:
-

参考文献/References:

[1] Leoni L M, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents[J]. Clin Cancer Res, 2008,14(1):309

[2] Derenzini E, Zinzani P L, Cheson B D. Bendamustine: role and evidence in lymphoma therapy, an overview[J]. Leuk Lymphoma, 2014,55(7):1471

[3] Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group[J]. J Clin Oncol, 2012,30(26):3209

[4] Reichmann U, Bokemeyer C, Wallwiener D, et al. Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine[J]. Ann Oncol, 2007,18(12):1981

[5] Berenson J R, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma[J]. Br J Haematol, 2013,160(3):321

[6] Maddocks K, Christian B, Jaglowski S, et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma[J]. Blood, 2015,125(2):242

[7] Cheson B D, Crawford J. A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas[J]. Br J Haematol, 2015,169(4):528

[8] Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group[J]. J Clin Oncol, 2012,30(26):3209

[9] Fraser C, Brown P, Megason G, et al. Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability[J]. J Pediatr Hematol Oncol, 2014,36(4):e212

[10] Owen J S, Melhem M, Passarell J A, et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma[J]. Cancer Chemother Pharmacol, 2010,66(6):1039

[11] van der Jagt R. Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes[J]. Expert Rev Hematol, 2013,6(5):525

[12] Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy[J]. Pharmacol Ther, 2005,107(2):155

[13] Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies[J]. Semin Oncol, 2002,29(4 Suppl 13):4

[14] Hsiao L T, Tien H F, Kuo C Y, et al. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma[J]. Hematol Oncol, 2014. [Epub ahead of print]

[15] 王晓坤. 新型抗肿瘤药物——苯达莫司汀[J]. 齐鲁药事, 2009(9):573

[16] Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours[J]. Br J Cancer, 2007,96(11):1692

[17] Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride[J]. Cancer Chemother Pharmacol, 2007,59(6):759

[18] Teichert J, Sohr R, Baumann F, et al. Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma[J]. Drug Metab Dispos, 2005,33(7):984

[19] Dubbelman A C, Rosing H, Darwish M, et al. Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy[J]. Drugs R D, 2013,13(1):17

[20] Kerb R, Brinkmann U, Chatskaia N, et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences[J]. Pharmacogenetics, 2002,12(8):591

[21] Du Plessis M, Pearce B, Jacobs C, et al. Genetic polymorphisms of the organic cation transporter 1 gene (SLC22A1) within the Cape Admixed population of South Africa[J]. Mol Biol Rep, 2015,42(3):665

[22] Giannoudis A, Wang L, Jorgensen A L, et al. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia[J]. Blood, 2013,121(4):628

[23] Vine J, Cohen S B, Ruchlemer R, et al. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia[J]. Leuk Lymphoma, 2014,55(11):2525

[24] Di Paolo A, Polillo M, Capecchi M, et al. The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia[J]. Pharmacogenomics J, 2014,14(4):328

[25] Arimany-Nardi C, Montraveta A, Lee-Verges E, et al. Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells[J]. Pharmacogenomics J, 2015.，15(4):363

[26] 周宏灏，肖鹏. 细胞色素氧化酶CYP1A2的研究进展[J]. 中南大学学报(医学版), 2008，33(5):456

[27] Zhou S F, Wang B, Yang L P, et al. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2[J]. Drug Metab Rev, 2010,42(2):268

[28] Sauna Z E, Kimchi-Sarfaty C, Ambudkar S V, et al. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer[J]. Cancer Res, 2007,67(20):9609

[29] 倪丽艳，李珊珊，严杨艳. 温州地区汉族正常人群CYP1A2基因多态性分布特征[J]. 中国优生与遗传杂志, 2012，20(7):14

[30] Song L, Du Q, Jiang X, et al. Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers[J]. J Clin Pharm Ther, 2014,39(2):204

[31] Liu J, Xi H, Jiang Y, et al. Association of CYP450 single nucleotide polymorphisms with the efficacy of epidural ropivacaine during mastectomy[J]. Acta Anaesthesiol Scand, 2015,59(5):640

[32] Goricar K, Kovac V, Jazbec J, et al. Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma[J]. Cancer Epidemiol, 2015,39(2):182

[33] Xiao Q, Deng D, Li H, et al. GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis[J]. Ann Hematol, 2014,93(8):1381

[34] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013,63(1):11

[35] 张晓波，杨崇礼. 全国白血病发病情况调查[J]. 中国医学科学院学报, 1992，14(1):12

[36] Alexander D D, Mink P J, Adami H O, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature[J]. Int J Cancer, 2007,120（ Suppl 12）:1

[37] 朱雄增，李小秋，李甘地. 中国淋巴瘤亚型分布:国内多中心性病例10002例分析[J]. 诊断学理论与实践, 2012，11(2):111

[38] Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group[J]. J Clin Oncol, 2011,29(26):3559

[39] Soini E J, Martikainen J A, Vihervaara V, et al. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma[J]. Clin Ther, 2012,34(4):915

相似文献/References:

[1]任 杰 综述,刘原君,刘全忠 审校.沙眼衣原体对宿主细胞抑癌基因p53影响的研究进展[J].天津医科大学学报,2016,22(06):544.

备注/Memo

备注/Memo:
?基金项目 天津市卫生行业重点攻关项目（14KG140）

作者简介 徐辉（1989-），男，硕士在读，研究方向：临床药学；通信作者：阎昭， E-mail ：yanzhao@tjmuch.com。

更新日期/Last Update: 2016-03-24